睿知中国疾病研究地图
候选清单0

正在招募胃癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04997837,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ

    入选标准第 4 条

  3. Positive lymph nodes more than 7, stage pN3

    入选标准第 5 条

  4. Patients after standard D2/R0 resection

    入选标准第 3 条

  5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1

    入选标准第 1 条

  6. Patients' blood routine and biochemical indicators should meet the following standard: Hb≥90g/L, ANC≥1.5*10\^9/L, PLT≥100*10\^9/L, ALT \& AST≤2.5 U/L, TB ≤ 1.5 UNL, serum creatinine<1 UNL.

    入选标准第 8 条

  7. Patient diagnosed with other malignant tumor in the past 5 years, excluding radical basal cell carcinoma of the skin and/or radical resected carcinoma in situ.

    排除标准第 7 条

    Patient with known HIV infection, or active tuberculosis.

    排除标准第 11 条

    Patient with active HCV infection

    排除标准第 13 条

  8. Pregnant or lactation period

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04997837,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
  2. Patients with expected survival time more than 6 months
  3. Patients after standard D2/R0 resection
  4. Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ
  5. Positive lymph nodes more than 7, stage pN3
  6. Patients without distant metastasis (M0) or M1 with abdominal exfoliated cell detection positive (CY1P0)
  7. Patients' physical condition and visceral function allows following adjuvant therapy, including chemotherapy, chemoradiotherapy and PD-1 inhibitor therapy.
  8. Patients' blood routine and biochemical indicators should meet the following standard: Hb≥90g/L, ANC≥1.5*10\^9/L, PLT≥100*10\^9/L, ALT \& AST≤2.5 U/L, TB ≤ 1.5 UNL, serum creatinine<1 UNL.
  9. Patients who are willing to obey regimens during the study.
  10. Written informed consent is acquired before random entry, and patients should know that he/she has the right to quit, and following treatment won't be affected.
  11. Patients are willing to provide samples of blood and tissue.

排除标准:Exclusion Criteria:

  1. Patients with gross peritoneal metastasis (CY1P0 excluded) or distant metastasis.
  2. Patients who has received any anti-tumor therapy before surgery.
  3. Patients who had received radiotherapy for abdominal organs including stomach, liver, kidney, etc.
  4. Patients who had active systematic autoimmune diseases which need systematic treatment within 2 years before first medication in the study, substitutive therapy (such as thyroxine, insulin, etc) excluded.
  5. Patients diagnosed with immunodeficiency, or was receiving systematic glucocorticoid treatment or other immunosuppressive therapy within 7 days before medication, physiological dose of glucocorticoid is allowed (≤10 mg/d prednison or equivalent medication)
  6. Patients who have known severe allergic reaction (≥level 3) to anti-PD-1 monoclonal antibody, 5-FU, Oxaliplatin or any auxiliary material.
  7. Patient diagnosed with other malignant tumor in the past 5 years, excluding radical basal cell carcinoma of the skin and/or radical resected carcinoma in situ.
  8. Patient with severe vital organ failure.
  9. Pregnant or lactation period
  10. Patient with known mental illness or drug abuse that may influence compliance.
  11. Patient with known HIV infection, or active tuberculosis.
  12. Untreated active hepatitis B
  13. Patient with active HCV infection
  14. Uncontrolled complications
  15. Other situations that might disturb study results and compliance.

引自 ClinicalTrials.gov, NCT04997837, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04997837,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04997837